{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:23:28Z","timestamp":1787952208495,"version":"build-2784847793"},"reference-count":76,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci Atheroscler Dis"],"abstract":"<jats:p>Systemic sclerosis (SSc) is an autoimmune disorder causing immune dysregulation, leading to microvascular damage and fibrosis. Cardiovascular involvement begins with endothelial dysfunction and progresses to vasospasm, ischemia, and fibrosis, impairing cardiac function. Common manifestations include myocardial fibrosis, conduction abnormalities, heart failure, and valvular dysfunction, affecting 15\u201335% of patients and contributing to 27.2% of SSc-related deaths. High-risk factors include male gender, older disease onset, African American ethnicity, diffuse cutaneous SSc, and poor quality of life. Subclinical cardiac dysfunction is common but underdiagnosed, and cardiovascular complications worsen outcomes. Pulmonary arterial hypertension is a major cause of morbidity and mortality and requires early diagnosis and multidisciplinary management. Treatments include calcium channel blockers, phosphodiesterase inhibitors, endothelin receptor antagonists, and prostacyclin analogs. Imaging (echocardiography, cardiac MRI, stress tests) and biomarkers (troponin, NT-proBNP, endothelin-1) help in diagnosis and monitoring. Early recognition and comprehensive management improve patient outcomes.<\/jats:p>","DOI":"10.5114\/amsad\/209030","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:54:18Z","timestamp":1758282858000},"page":"121-138","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac disease in systemic sclerosis: a narrative review"],"prefix":"10.5114","volume":"10","author":[{"given":"Azka","family":"Naeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3490-9557","authenticated-orcid":true,"given":"Muhammad Hashim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omair","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mujtaba","family":"Baqir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheharyar","family":"Raashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon Rivera","family":"Boadla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayiwola","family":"Bolaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mohammad","family":"Mazhar-uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref-1518453","doi-asserted-by":"crossref","unstructured":"Romano E, Rosa I, Fioretto BS, Manetti M. Recent insights into cellular and molecular mechanisms of defective angiogenesis in systemic sclerosis. Biomedicines 2024; 12: 1331.","DOI":"10.3390\/biomedicines12061331"},{"key":"ref-1518454","doi-asserted-by":"crossref","unstructured":"Son HH, Moon SJ. Pathogenesis of systemic sclerosis: an integrative review of recent advances. J Rheum Dis 2025; 32: 89-104.","DOI":"10.4078\/jrd.2024.0129"},{"key":"ref-1518455","doi-asserted-by":"crossref","unstructured":"Ko J, Noviani M, Chellamuthu VR, Albani S, Low AHL. The pathogenesis of systemic sclerosis: the origin of fibrosis and interlink with vasculopathy and autoimmunity. Int J Mol Sci 2023; 24: 14287.","DOI":"10.3390\/ijms241814287"},{"key":"ref-1518456","doi-asserted-by":"crossref","unstructured":"Lambova S. Cardiac manifestations in systemic sclerosis. World J Cardiol 2014; 6: 993-1005.","DOI":"10.4330\/wjc.v6.i9.993"},{"key":"ref-1518457","doi-asserted-by":"crossref","unstructured":"Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 2011; 4: 67-76.","DOI":"10.1161\/CIRCIMAGING.110.960740"},{"key":"ref-1518458","doi-asserted-by":"crossref","unstructured":"Moysidou GS, Dara A, Arvanitaki A, et al. Understanding and managing cardiac involvement in systemic sclerosis. Expert Rev Clin Immunol 2023; 19: 293-304.","DOI":"10.1080\/1744666X.2023.2171988"},{"key":"ref-1518459","unstructured":"Furst DE, Khanna D, Clements PJ, et al. Update on the management of systemic sclerosis with severe organ involvement. Arthritis Res Ther 2021; 23: 84."},{"key":"ref-1518460","doi-asserted-by":"crossref","unstructured":"Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-50.","DOI":"10.1002\/art.22069"},{"key":"ref-1518461","unstructured":"Doughty RN, Whalley GA, Klein AL, et al. Right ventricular function in cor pulmonale: advances in assessment and treatment. Am J Respir Crit Care Med 2020; 201: 281-92."},{"key":"ref-1518462","unstructured":"Moran E, Badran M, Moustafa S, et al. Right ventricular function and its role in the management of pulmonary hypertension and cor pulmonale. J Am Coll Cardiol 2022; 79: 1340-52."},{"key":"ref-1518463","doi-asserted-by":"crossref","unstructured":"Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008; 34: 41-55; vi.","DOI":"10.1016\/j.rdc.2008.01.001"},{"key":"ref-1518464","doi-asserted-by":"crossref","unstructured":"Cabral-Marques O, Riemekasten G. Vascular hypothesis revisited: role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmun Rev 2016; 15: 690-4.","DOI":"10.1016\/j.autrev.2016.03.005"},{"key":"ref-1518465","doi-asserted-by":"crossref","unstructured":"De Luca G, Cavalli G, Campochiaro C, et al. Interleukin-1 and systemic sclerosis: getting to the heart of cardiac involvement. Front Immunol 2021; 12: 653950.","DOI":"10.3389\/fimmu.2021.653950"},{"key":"ref-1518466","doi-asserted-by":"crossref","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685-99.","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"ref-1518467","doi-asserted-by":"crossref","unstructured":"Civieri G, Iop L, Tona F. Antibodies against angiotensin II type 1 and endothelin 1 type A receptors in cardiovascular pathologies. Int J Mol Sci 2022; 23: 927.","DOI":"10.3390\/ijms23020927"},{"key":"ref-1518468","doi-asserted-by":"crossref","unstructured":"Tavernese A, Cammalleri V, Mollace R, et al. The role of advanced cardiac imaging in monitoring cardiovascular complications in patients with extracardiac tumors: a descriptive review. J Cardiovasc Develop Dis 2025; 12: 9.","DOI":"10.3390\/jcdd12010009"},{"key":"ref-1518469","doi-asserted-by":"crossref","unstructured":"Pan SY, Tian HM, Zhu Y, et al. Cardiac damage in autoimmune diseases: target organ involvement that cannot be ignored. Front Immunol 2022; 13: 1056400.","DOI":"10.3389\/fimmu.2022.1056400"},{"key":"ref-1518470","doi-asserted-by":"crossref","unstructured":"H\u00f6ppner J, Tabeling C, Casteleyn V, et al. Comprehensive autoantibody profiles in systemic sclerosis: clinical cluster analysis. Front Immunol 2023; 13: 1045523.","DOI":"10.3389\/fimmu.2022.1045523"},{"key":"ref-1518471","unstructured":"Ehrlich D, Gali\u00f1anes M, Wilson E, et al. Myocardial involvement in systemic sclerosis: new insights into pathogenesis and management. J Am Coll Cardiol 2022; 80: 1057-68."},{"key":"ref-1518472","unstructured":"Gordon JK, Domsic RT, Lee J, et al. Cardiac conduction system abnormalities in systemic sclerosis: clinical and pathological insights. J Cardiac Fail 2021; 27: 1340-9."},{"key":"ref-1518473","doi-asserted-by":"crossref","unstructured":"Bruni C, Buch MH, Djokovic A, et al. Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation\/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. J Scleroderma Relat Disord 2023; 8: 169-82.","DOI":"10.1177\/23971983231163413"},{"key":"ref-1518474","doi-asserted-by":"crossref","unstructured":"Draeger HT, Assassi S, Sharif R, et al. Right bundle branch block: a predictor of mortality in early systemic sclerosis. PLoS One 2013; 8: e78808.","DOI":"10.1371\/journal.pone.0078808"},{"key":"ref-1518475","unstructured":"Bolk N, Van der Leij C, Smulders Y, et al. Electrocardiographic abnormalities in systemic sclerosis: a study of 150 consecutive cases with functional correlations and updated review. Eur Heart J Digital Health 2022; 43: 1200-10."},{"key":"ref-1518476","doi-asserted-by":"crossref","unstructured":"Mavrogeni S, Gargani L, Pepe A, et al. Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology (Oxford) 2020; 59: 1938-48.","DOI":"10.1093\/rheumatology\/kez494"},{"key":"ref-1518477","doi-asserted-by":"crossref","unstructured":"Ferri C, Giuggioli D, Sebastiani M, Colaci M, Emdin M. Heart involvement and systemic sclerosis. Lupus 2005; 14: 702-7.","DOI":"10.1191\/0961203305lu2204oa"},{"key":"ref-1518478","doi-asserted-by":"crossref","unstructured":"Bissell LA, Anderson M, Burgess M, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 2017; 56: 912-21.","DOI":"10.1093\/rheumatology\/kew488"},{"key":"ref-1518479","doi-asserted-by":"crossref","unstructured":"Glynn P, Hale S, Hussain T, Freed BH. Cardiovascular imaging for systemic sclerosis monitoring and management. Front Cardiovasc Med 2022; 9: 846213.","DOI":"10.3389\/fcvm.2022.846213"},{"key":"ref-1518480","doi-asserted-by":"crossref","unstructured":"Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 218-21.","DOI":"10.1136\/ard.2008.103382"},{"key":"ref-1518481","doi-asserted-by":"crossref","unstructured":"Yiu KH, Schouffoer AA, Marsan NA, et al. Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias. Arthritis Rheum 2011; 63: 3969-78.","DOI":"10.1002\/art.30614"},{"key":"ref-1518482","doi-asserted-by":"crossref","unstructured":"Meier C, Eisenbl\u00e4tter M, Gielen S. Myocardial late gadolinium enhancement (LGE) in cardiac magnetic resonance imaging (CMR)-an important risk marker for cardiac disease. J Cardiovasc Dev Dis 2024; 11: 40.","DOI":"10.3390\/jcdd11020040"},{"key":"ref-1518483","doi-asserted-by":"crossref","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503-626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"ref-1518484","doi-asserted-by":"crossref","unstructured":"Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68: 1878-84.","DOI":"10.1136\/ard.2008.095836"},{"key":"ref-1518485","doi-asserted-by":"crossref","unstructured":"Masri MFB, Ng SA, Chin CW, Low AH. Biomarkers in the evaluation of cardiac involvement in systemic sclerosis. Rheumatol Immunol Res 2024; 5: 99-106.","DOI":"10.1515\/rir-2024-0013"},{"key":"ref-1518486","doi-asserted-by":"crossref","unstructured":"Tyndall AJ, Bannert B, Vonk M. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809.","DOI":"10.1136\/ard.2009.114264"},{"key":"ref-1518487","doi-asserted-by":"crossref","unstructured":"Webber M, Jackson SP, Moon JC, Captur G. Myocardial fibrosis in heart failure: anti-fibrotic therapies and the role of cardiovascular magnetic resonance in drug trials. Cardiol Ther 2020; 9: 363-76.","DOI":"10.1007\/s40119-020-00199-y"},{"key":"ref-1518488","doi-asserted-by":"crossref","unstructured":"Bergonti M, Ciconte G, Cruzalegui Gomez J, et al. Continuous rhythm monitoring with implanted loop recorders in children and adolescents with Brugada syndrome. J Am Coll Cardiol 2024; 84: 921-33.","DOI":"10.1016\/j.jacc.2024.04.070"},{"key":"ref-1518489","doi-asserted-by":"crossref","unstructured":"Bournia VK, Tountas C, Protogerou AD, et al. Update on assessment and management of primary cardiac involvement in systemic sclerosis. J scleroderma Relat Disord 2018; 3: 53-65.","DOI":"10.1177\/2397198317747441"},{"key":"ref-1518490","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.","DOI":"10.1056\/NEJMoa055120"},{"key":"ref-1518491","doi-asserted-by":"crossref","unstructured":"Namas R, Tashkin DP, Furst DE, et al.; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo- controlled trials. Arthritis Care Res (Hoboken) 2018; 70: 439-44.","DOI":"10.1002\/acr.23282"},{"key":"ref-1518492","doi-asserted-by":"crossref","unstructured":"van Laar JM, Farge D, Sont JK, et al. EBMT\/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8.","DOI":"10.1001\/jama.2014.6368"},{"key":"ref-1518493","doi-asserted-by":"crossref","unstructured":"Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 1038-43.","DOI":"10.1093\/rheumatology\/40.9.1038"},{"key":"ref-1518494","doi-asserted-by":"crossref","unstructured":"Curtiss P, Schwager Z, Cobos G, et al. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud\u2019s phenomenon. J Am Acad Dermatol 2018; 78: 1110.e3-8.e3.","DOI":"10.1016\/j.jaad.2018.01.043"},{"key":"ref-1518495","doi-asserted-by":"crossref","unstructured":"Bruni C, Ross L. Cardiac involvement in systemic sclerosis: getting to the heart of the matter. Best Pract Res Clin Rheumatol 2021; 35: 101668.","DOI":"10.1016\/j.berh.2021.101668"},{"key":"ref-1518496","doi-asserted-by":"crossref","unstructured":"Cassius C, Seta V, Monfort JB, et al. Systemic sclerosis is associated with lower limb vascular stiffness and microvascular impairment: results from a prospective study. Clin Rheumatol 2021; 40: 3679-86.","DOI":"10.1007\/s10067-021-05672-0"},{"key":"ref-1518497","doi-asserted-by":"crossref","unstructured":"Ranasinghe ADCU, Tennakoon TMPB, Schwarz MA. Emerging epigenetic targets and their molecular impact on vascular remodeling in pulmonary hypertension. Cells 2024; 13: 244.","DOI":"10.3390\/cells13030244"},{"key":"ref-1518498","unstructured":"Bolk N, Ponda M, Black H, et al. Cardiac and skeletal muscle disease in systemic sclerosis: updated risk associations and outcomes. Am J Cardiol 2022; 142: 755-64."},{"key":"ref-1518499","doi-asserted-by":"crossref","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384: 325-34.","DOI":"10.1056\/NEJMoa2008470"},{"key":"ref-1518500","doi-asserted-by":"crossref","unstructured":"Bahi M, Li C, Wang G, Korman BD. Systemic sclerosis-associated pulmonary arterial hypertension: from bedside to bench and back again. Int J Mol Sci 2024; 25: 4728.","DOI":"10.3390\/ijms25094728"},{"key":"ref-1518501","doi-asserted-by":"crossref","unstructured":"Haque A, Kiely DG, Kovacs G, Thompson AAR, Condliffe R. Pulmonary hypertension phenotypes in patients with systemic sclerosis. Eur Respir Rev 2021; 30: 210053.","DOI":"10.1183\/16000617.0053-2021"},{"key":"ref-1518502","doi-asserted-by":"crossref","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet 2023; 401: 304-18.","DOI":"10.1016\/S0140-6736(22)01692-0"},{"key":"ref-1518503","doi-asserted-by":"crossref","unstructured":"Medarov BI, Judson MA. The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: how much do we actually know and how could they be positioned today? Respir Med 2015; 109: 557-64.","DOI":"10.1016\/j.rmed.2015.01.004"},{"key":"ref-1518504","doi-asserted-by":"crossref","unstructured":"Lechartier B, Humbert M. Pulmonary arterial hypertension in systemic sclerosis. Presse Med 2021; 50: 104062.","DOI":"10.1016\/j.lpm.2021.104062"},{"key":"ref-1518505","doi-asserted-by":"crossref","unstructured":"Naranjo M, Hassoun PM. Systemic sclerosis-associated pulmonary hypertension: spectrum and impact. Diagnostics 2021; 11: 911.","DOI":"10.3390\/diagnostics11050911"},{"key":"ref-1518506","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-61.","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref-1518507","doi-asserted-by":"crossref","unstructured":"Saygin D, Domsic RT. Pulmonary arterial hypertension in systemic sclerosis: challenges in diagnosis, screening and treatment. Open Access Rheumatol 2019; 11: 323-33.","DOI":"10.2147\/OARRR.S228234"},{"key":"ref-1518508","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. [2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. G Ital Cardiol (Rome) 2023; 24: 1e-116e."},{"key":"ref-1518509","doi-asserted-by":"crossref","unstructured":"Bauer Y, de Bernard S, Hickey P, et al. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. Eur Respir J 2021; 57: 2002591.","DOI":"10.1183\/13993003.02591-2020"},{"key":"ref-1518510","doi-asserted-by":"crossref","unstructured":"Vilela VS, Dias MM, Salgado AA, et al. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. BMC Pulm Med 2021; 21: 251.","DOI":"10.1186\/s12890-021-01618-z"},{"key":"ref-1518511","doi-asserted-by":"crossref","unstructured":"Almaaitah S, Highland KB, Tonelli AR. Management of pulmonary arterial hypertension in patients with systemic sclerosis. Integr Blood Press Control 2020; 13: 15-29.","DOI":"10.2147\/IBPC.S232038"},{"key":"ref-1518512","doi-asserted-by":"crossref","unstructured":"Lian TY, Jiang X, Jing ZC. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther 2017; 11: 1195-207.","DOI":"10.2147\/DDDT.S117277"},{"key":"ref-1518513","unstructured":"ClinicalTrials.gov. A phase 2 multicenter, randomized, double-blind, placebo- controlled study to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH). NCT02682511 Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02682511. Accessed March 6, 2020."},{"key":"ref-1518514","doi-asserted-by":"crossref","unstructured":"Zamanian R, Badesch D, Chung L, et al. Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2019; 54 (Suppl 63): RCT1884.","DOI":"10.1183\/13993003.congress-2019.RCT1884"},{"key":"ref-1518515","unstructured":"ClinicalTrials.gov. A dose-ranging study of the efficacy and safety of bardoxolone methyl in patients with pulmonary hypertension. NCT02036970 [May 16, 2018]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02036970. Accessed March6, 2020."},{"key":"ref-1518516","doi-asserted-by":"crossref","unstructured":"Wang MT, Weng KP, Chang SK, Huang WC, Chen LW. Hemodynamic and clinical profiles of pulmonary arterial hypertension patients with GDF2 and BMPR2 variants. Int J Mol Sci 2024; 25: 2734.","DOI":"10.3390\/ijms25052734"},{"key":"ref-1518517","unstructured":"Avouac J, Air\u00f2 P, Czirj\u00e1k L, et al. Cardiac involvement in systemic sclerosis: updated insights on diagnosis and management. Curr Opin Rheumatol 2022; 34: 413-23."},{"key":"ref-1518518","unstructured":"Tyndel S, Schreiber BE, Williams C, et al. Physiologic abnormalities of cardiac function in systemic sclerosis: insights from recent studies. J Am Coll Cardiol 2023; 81: 185-96."},{"key":"ref-1518519","doi-asserted-by":"crossref","unstructured":"Steen V. The heart in systemic sclerosis. Curr Rheumatol Rep 2004; 6: 137-40.","DOI":"10.1007\/s11926-004-0058-4"},{"key":"ref-1518520","doi-asserted-by":"crossref","unstructured":"Mewton N, Liu CY, Croisille P, Bluemke D, Lima JAC. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011; 57: 891-903.","DOI":"10.1016\/j.jacc.2010.11.013"},{"key":"ref-1518521","doi-asserted-by":"crossref","unstructured":"Rangarajan V, Matiasz R, Freed BH. Cardiac complications of systemic sclerosis and management: recent progress. Curr Opin Rheumatol 2017; 29: 574-84.","DOI":"10.1097\/BOR.0000000000000439"},{"key":"ref-1518522","doi-asserted-by":"crossref","unstructured":"Galie N, Simonneau G. The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl): D1-3.","DOI":"10.1016\/j.jacc.2013.10.030"},{"key":"ref-1518523","doi-asserted-by":"crossref","unstructured":"Lim MWS, Setjiadi D, Dobbin SJH, Lang NN, Delles C, Connelly PJ. Nailfold videocapillaroscopy in the study of cardiovascular disease: a systematic review. Blood Press Monit 2023; 28: 24-32.","DOI":"10.1097\/MBP.0000000000000624"},{"key":"ref-1518524","doi-asserted-by":"crossref","unstructured":"Minopoulou I, Theodorakopoulou M, Boutou A, et al. Nailfold capillaroscopy in systemic sclerosis patients with and without pulmonary arterial hypertension: a systematic review and meta-analysis. J Clin Med 2021; 10: 1528.","DOI":"10.3390\/jcm10071528"},{"key":"ref-1518525","doi-asserted-by":"crossref","unstructured":"Lambova SN, M\u00fcller-Ladner U. Nailfold capillaroscopy in systemic sclerosis \u2013 state of the art: the evolving knowledge about capillaroscopic abnormalities in systemic sclerosis. J Scleroderma Relat Disord 2019; 4: 200-11.","DOI":"10.1177\/2397198319833486"},{"key":"ref-1518526","doi-asserted-by":"crossref","unstructured":"Valentini G, Huscher D, Riccardi A, et al. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis 2019; 78: 1576-82.","DOI":"10.1136\/annrheumdis-2019-215486"},{"key":"ref-1518527","doi-asserted-by":"crossref","unstructured":"Allanore Y, Avouac J, Kahan A. Systemic sclerosis: an update in 2008. Joint Bone Spine 2008; 75: 650-5.","DOI":"10.1016\/j.jbspin.2008.07.003"},{"key":"ref-1518528","doi-asserted-by":"crossref","unstructured":"Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-7.","DOI":"10.1164\/rccm.200806-953OC"}],"container-title":["Archives of Medical Science \u2013 Atherosclerotic Diseases"],"original-title":[],"link":[{"URL":"https:\/\/amsad.termedia.pl\/pdf-209030-128801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/amsad.termedia.pl\/pdf-209030-128801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:54:35Z","timestamp":1758282875000},"score":1,"resource":{"primary":{"URL":"https:\/\/amsad.termedia.pl\/Cardiac-disease-in-systemic-sclerosis-a-narrative-review,209030,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"alternative-id":["209030"],"URL":"https:\/\/doi.org\/10.5114\/amsad\/209030","relation":{},"ISSN":["2451-0629"],"issn-type":[{"value":"2451-0629","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}